Hepatic metabolic effects of norepinephrine are potentiated by nitric oxide.
Patarrão
R S
RS
Instituto Superior de Ciências da Saúde-Sul, Quinta da Granja, 2825 Monte da Caparica, Portugal.
Macedo
M P
MP
Raposo
J F
JF
Carmo
M M
MM
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology*; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D006152:Cyclic GMP / Q000031:analogs & derivatives* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004789:Enzyme Activation / Q000187:drug effects; D005947:Glucose / Q000378:metabolism; D006162:Guanylate Cyclase / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D009569:Nitric Oxide / Q000494:pharmacology*; D009638:Norepinephrine / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D020239:Receptor Cross-Talk / Q000187:drug effects
D000316:Adrenergic alpha-Agonists; D001786:Blood Glucose; C016276:8-bromocyclic GMP; D009569:Nitric Oxide; D006162:Guanylate Cyclase; D006152:Cyclic GMP; D005947:Glucose; D009638:Norepinephrine